Oxeia to Enroll 160 Patients in Concussion Symptom Therapy Clinical Trial
Oxeia Biopharmaceuticals plans to enroll 160 patients in a Phase 2b clinical trial of OXE103 beginning in 2026, advancing what could become the first approved therapy for persistent concussion symptoms following promising Phase 2a results.